Best peptides for anti-aging
Peptides that support longevity markers, skin health, cognitive function, and overall healthspan extension.
What to know
GHK-Cu has the strongest topical anti-aging evidence (collagen synthesis, wound healing, gene modulation). Epithalon targets telomere extension through telomerase activation — research is promising but early. MOTS-c and SS-31 target mitochondrial function, which declines with age. Anti-aging peptide protocols tend to be longer-term (6+ months) and stack multiple compounds targeting different aging pathways.
Recommended peptides
GHK-Cu
anti-aging
GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex discovered in 1973 by biochemist Loren Pickart. His laboratory found that older human liver tissue exposed to GHK-Cu produced proteins more characteristic of younger tissue — a finding that launched over five decades of continuous research into this peptide's regenerative properties. The molecule consists of three amino acids (glycine, histidine, lysine) bound to a copper(II) ion, and it occurs naturally in human plasma, saliva, and urine. In young adults, circulating GHK-Cu levels average approximately 200 ng/mL. By age 60, those levels decline to roughly 80 ng/mL — a reduction of more than 60% that correlates with visible signs of aging and diminished tissue repair capacity (PMID: 35083444). GHK-Cu is one of the most broadly studied peptides in the research literature, with effects documented across skin, lung, bone, liver, stomach, and nervous system tissue. Gene profiling studies using the Broad Institute Connectivity Map have identified over 4,000 human genes whose expression changes in response to GHK-Cu treatment, making it one of the most broadly active gene modulators among known bioactive peptides (PMID: 26236730). Key pathways with direct experimental confirmation include collagen synthesis, DNA repair, antioxidant defense, inflammatory signaling, and cellular senescence — though not all 4,000+ gene changes have been individually validated beyond the computational profiling. The strongest evidence clusters around four areas: skin regeneration and anti-aging (with collagen synthesis data dating to 1988), wound healing (across multiple tissue types), lung protection and COPD reversal (four separate studies demonstrating gene expression normalization in diseased lung tissue), and gene modulation (three major reviews covering the 4,000+ gene dataset). A 2025 study extended the research into gastrointestinal health, demonstrating GHK-Cu's ability to alleviate ulcerative colitis in mice through the SIRT1/STAT3 pathway (PMID: 40672369). In the cancer research context, GHK-Cu presents a paradox that warrants caution. While it promotes angiogenesis (blood vessel growth) — which could theoretically support tumor growth — a computational gene expression screen (Connectivity Map) of 1,309 bioactive compounds found that GHK was one of only two whose transcriptional profile reversed a 54-gene metastatic signature in colorectal cancer (PMID: 20143136). This reflects gene expression pattern matching, not direct anti-cancer testing, and no follow-up cancer model studies have been published since 2010. Individuals with active or suspected cancer should consult their oncologist before using GHK-Cu. GHK-Cu is available in multiple delivery formats. Topical serums and creams (typically 1-3% concentration) represent the most common and well-studied application, with decades of published human data supporting skin improvements. Injectable GHK-Cu provides systemic delivery at higher tissue concentrations but relies primarily on animal and in vitro evidence for most indications. Microneedling combined with topical GHK-Cu has emerged as a popular middle-ground approach, with research showing that microneedle-treated skin absorbs significantly more peptide than intact skin alone. GHK-Cu is also known by its cosmetic industry name, Copper Tripeptide-1 (INCI designation). Its chemical structure naturally occurs within the alpha 2(I) chain of type I collagen, suggesting that the body releases GHK-Cu at wound sites through proteolytic breakdown of damaged collagen — a built-in mechanism for initiating local repair (PMID: 3169264). The regulatory landscape for GHK-Cu differs between topical and injectable forms. Topical copper peptide products are classified as cosmetics and remain widely available over the counter. Injectable GHK-Cu was placed on the FDA's Category 2 list in September 2023, restricting compounding. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 Category 2 peptides would be reclassified back to Category 1 — GHK-Cu is on that list. As of March 2026, the formal FDA list update has not yet been published, with implementation expected through mid-2026. GHK-Cu has never been FDA-approved as a drug for any indication, and injectable use remains an off-label prescription through compounding pharmacies. GHK-Cu is not on the WADA prohibited list.
BPC-157
healing-recovery
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.
SS-31
anti-aging
SS-31 (Elamipretide) is a mitochondria-targeted peptide that restores mitochondrial function and has been studied in clinical trials for heart failure and mitochondrial diseases.
MOTS-c
metabolic
MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and has been called an "exercise mimetic" for its ability to activate AMPK pathways.
Get the Anti-Aging cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Recommended stacks
GH Optimization Stack
intermediate — $100-250
Growth hormone secretagogue stack combining GHRP and GHRH for synergistic GH release without exogenous HGH.
Anti-Aging Longevity Stack
advanced — $300-600
Multi-pathway anti-aging protocol targeting telomeres, mitochondrial function, skin health, and immune modulation.
Skin Rejuvenation Stack
beginner — $80-200
Targeted skin health protocol combining topical and systemic peptides for collagen production, wrinkle reduction, and skin repair.
The GH Optimization Stack
intermediate — $100-250
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) work through complementary receptor pathways to produce synergistic GH release without the side effects of exogenous HGH.
The Anti-Aging Stack
advanced — $300-600
Targets three core aging pathways simultaneously: epitalon activates telomerase to protect chromosomal integrity, GHK-Cu resets gene expression patterns toward a younger state, and SS-31 repairs mitochondrial function at the cellular level.
The Skin & Hair Stack
beginner — $60-180
A targeted protocol for skin elasticity and hair health. GHK-Cu is the most researched peptide for skin rejuvenation, modulating over 4,000 genes involved in tissue remodeling. Combined with collagen peptide supplementation for structural protein support.
Explore other goals
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026